Karen Wilson - Jazz Pharmaceuticals President
| JAZZ Stock | USD 109.94 0.67 0.61% |
President
Ms. Karen J. Wilson is the Senior Vice President Finance, Principal Accounting Officer of Jazz Pharmaceuticals PLC. Ms. Wilson was appointed our Senior Vice President, Finance and Principal Accounting Officer as of February 2013 and served as our Vice President, Finance and Principal Accounting Officer from the closing of the Azur Merger in January 2012 until February 2013. Prior to the Azur Merger, she served as Jazz Pharmaceuticals, Inc.s Vice President, Finance beginning in February 2011 and was appointed Principal Accounting Officer in March 2011. From 2009 to January 2011, she served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc., a biotechnology company. From 2005 to 2009, she served as a principal at the consulting firm Wilson Crisler LLC. Prior to that, from 2001 to 2004, she was Chief Financial Officer of ViroLogic, Inc., a biosciences company. Prior to joining ViroLogic, Ms. Wilson served as Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc. from 1999 to 2001. Prior to 1999, Ms. Wilson worked for Deloitte Touche LLP for ten years, serving clients in both the life sciences and technology fields since 2013.
| Age | 55 |
| Tenure | 11 years |
| Address | Waterloo Exchange, Dublin, Ireland, D04 E5W7 |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1216 %, meaning that it created $0.1216 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.5 B in 2024, despite the fact that Net Tangible Assets are likely to grow to (3.7 B).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| DavidAlexandre Gros | Neurocrine Biosciences | 43 | |
| Mark Stejbach | Alkermes Plc | 55 | |
| Mark Currie | Ironwood Pharmaceuticals | 63 | |
| Mark Namchuk | Alkermes Plc | N/A | |
| Robert Janssen | Dynavax Technologies | 70 | |
| CTodd Nichols | Alkermes Plc | N/A | |
| Adrian Hepner | Eagle Pharmaceuticals | 56 | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| Halley Gilbert | Ironwood Pharmaceuticals | 48 | |
| Shane Cooke | Alkermes Plc | 54 | |
| David Gaffin | Alkermes Plc | 52 | |
| Craig Hopkinson | Alkermes Plc | 49 | |
| Bill Aurora | Neurocrine Biosciences | N/A | |
| Elliot Ehrich | Alkermes Plc | 57 | |
| David Johnson | Dynavax Technologies | 56 | |
| Christopher Wright | Ironwood Pharmaceuticals | N/A | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Gordon Pugh | Alkermes Plc | 57 | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| Kelly MacDonald | Ironwood Pharmaceuticals | 34 | |
| Michael Landine | Alkermes Plc | 70 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0456 |
Jazz Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Diane Schrick, Senior Director, Investor Relations | ||
| Matthew Young, CFO and Executive VP | ||
| Finbar Larkin, VP Operations | ||
| Iain McGill, Senior Vice President - Jazz Pharmaceuticals Europe and Rest of World | ||
| Rick Winningham, Independent Director | ||
| Peter Gray, Independent Director | ||
| Katherine Littrell, Vice President - Investor Relations | ||
| Paul Treacy, Senior Vice President Technical Operations | ||
| Renee Gala, President COO | ||
| Robert MD, Executive Development | ||
| Robert Iannone, Executive Vice President Research and Development | ||
| Karen Wilson, Senior Vice President - Finance, Principal Accounting Officer | ||
| Rene Gal, President COO | ||
| Seamus Mulligan, Director | ||
| Russell Cox, COO and Executive VP | ||
| Karen Smith, Global Head of Research & Development and Chief Medical Officer | ||
| Neena JD, Executive Officer | ||
| Samantha Pearce, Senior International | ||
| George Eliades, Senior Officer | ||
| Paul Berns, Independent Director | ||
| Daniel Swisher, NonExecutive Employee | ||
| Anne ORiordan, Director | ||
| Suzanne Hooper, Executive VP and General Counsel | ||
| Patricia Carr, Senior Officer | ||
| Heather McSharry, Independent Director | ||
| Michael Miller, Sr. VP of U.S. Commercial | ||
| Jed MD, Senior Medicine | ||
| Andrea Flynn, VP Relations | ||
| Patrick Enright, Independent Director | ||
| Philip Johnson, Executive CFO | ||
| Norbert Riedel, Independent Director | ||
| Catherine Sohn, Independent Director | ||
| Heidi Manna, Executive Officer | ||
| Elmar Schnee, Independent Director | ||
| Kenneth OKeefe, Independent Director | ||
| Bruce Cozadd, Co-Founder, Executive Chairman and CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0456 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 10.98 B | ||||
| Shares Outstanding | 62.35 M | ||||
| Shares Owned By Insiders | 2.81 % | ||||
| Shares Owned By Institutions | 95.90 % | ||||
| Number Of Shares Shorted | 3.26 M | ||||
| Price To Earning | 35.18 X |
Jazz Pharmaceuticals Investors Sentiment
The influence of Jazz Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Jazz. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Jazz Pharmaceuticals' public news can be used to forecast risks associated with an investment in Jazz. The trend in average sentiment can be used to explain how an investor holding Jazz can time the market purely based on public headlines and social activities around Jazz Pharmaceuticals PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Jazz Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Jazz Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Jazz Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Jazz Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Jazz Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Jazz Pharmaceuticals' short interest history, or implied volatility extrapolated from Jazz Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.757 | Earnings Share 6.1 | Revenue Per Share 60.581 | Quarterly Revenue Growth 0.041 | Return On Assets 0.0456 |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.